Kingsview Wealth Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-206,252
Closed -$5.98M 1340
2025
Q4
$5.98M Buy
+206,252
New +$6.19M 0.09% 248
2021
Q4
Sell
-3,946
Closed -$295K 956
2021
Q3
$295K Sell
3,946
-589
-13% -$49.4K 0.01% 688
2021
Q2
$421K Sell
4,535
-7,209
-61% -$613K 0.02% 607
2021
Q1
$1.05M Buy
+11,744
New +$1.16M 0.06% 320

Other funds holding ARKG

Kingsview Wealth Management's ARKG Position: Q1 2026 in Review

Kingsview Wealth Management sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2026, closing a stake of 206,252 shares — an estimated $5.98M sold.

Kingsview Wealth Management first reported a position in ARKG in Q1 2021 and held it in 4 quarters. The position peaked at $5.98M in Q4 2025. 219 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.

  • Kingsview Wealth Management reported no remaining ARK Genomic Revolution ETF position as of Q1 2026 after selling out during the quarter.
  • Kingsview Wealth Management sold 206,252 ARK Genomic Revolution ETF shares in Q1 2026, an estimated $5.98M.
  • Kingsview Wealth Management first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 4 quarters.
  • Kingsview Wealth Management's ARK Genomic Revolution ETF position peaked at $5.98M in Q4 2025.
  • 219 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.

Based on Kingsview Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.